BofA analyst Alec Stranahan downgraded Intellia Therapeutics (NTLA) to Neutral from Buy with a price target of $14, down from $30. Intellia’s Phase 3 trial pause due to a Grade 4 liver safety event and subsequent FDA clinical hold has weighed on shares, notes the analyst, who points out that nex-z, Intellia’s “largest value driver,” is now delayed likely for at least a few months with a potentially more complicated path to market. While the firm still has value for HAE in its model, the analyst also notes there is a risk to this program if safety issues are not related to the target, as the company has suggested, but instead the lipid nanoparticle or something common between programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $9 from $14 at Wedbush
- Intellia Therapeutics price target lowered to $18 from $25 at H.C. Wainwright
- Intellia Therapeutics Faces FDA Clinical Hold on Trials
- Cathie Wood Boosts Biotech Bets, Cuts Back on Tech Favorites, Including Shopify and Palantir (PLTR)
- Cathie Wood’s ARK Investment buys 479.4K shares of Intellia Therapeutics today